Xiangguo Qiu

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. pmc Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 88:12703-14. 2014
  2. doi request reprint Two-mAb cocktail protects macaques against the Makona variant of Ebola virus
    Xiangguo Qiu
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 8:329ra33. 2016
  3. pmc Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
  4. doi request reprint Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
  5. doi request reprint mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 5:207ra143. 2013
  6. pmc Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Rep 3:3365. 2013
  7. doi request reprint Development and Characterization of a Guinea Pig-Adapted Sudan Virus
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 90:392-9. 2015
  8. doi request reprint Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology
    J Infect Dis 212:S379-83. 2015
  9. pmc Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
    Xiangguo Qiu
    National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Nature 514:47-53. 2014
  10. doi request reprint Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Vaccine 32:5722-9. 2014

Collaborators

  • Gary P Kobinger
  • Steven M Jones
  • Heinz Feldmann
  • Ute Stroher
  • Jiannan Feng
  • Yi Zhang
  • Ayato Takada
  • Gary Wong
  • Jonathan Audet
  • Jason S Richardson
  • Jenna Aviles
  • Todd Cutts
  • Lisa Fernando
  • Emelissa J Mendoza
  • Carissa Embury-Hyatt
  • Marc Antoine de La Vega
  • Hugues Fausther-Bovendo
  • Judie B Alimonti
  • Stéphane Pillet
  • Ami Patel
  • Jill Graham
  • Jeffrey Turner
  • Anders Leung
  • Kinola J N Williams
  • Brad Collignon
  • Friederike Feldmann
  • Jason Gren
  • Haiyan Wei
  • Trina Racine
  • Darwyn Kobasa
  • Jane Ennis
  • Geoff Soule
  • Shihua He
  • P Leno Melito
  • Andrea Kroeker
  • Alexander Bello
  • Hideki Ebihara
  • Gene G Olinger
  • Han Wang
  • Guangwen Lu
  • George F Gao
  • Judie Alimonti
  • Jeff Hogan

Detail Information

Publications25

  1. pmc Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 88:12703-14. 2014
    ..This model provides an important tool to screen candidate vaccines and therapeutics against MARV infections...
  2. doi request reprint Two-mAb cocktail protects macaques against the Makona variant of Ebola virus
    Xiangguo Qiu
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 8:329ra33. 2016
    ..The chimeric MIL77E mAb cocktail is produced in engineered Chinese hamster ovary cells and is based on mAbs c13C6 and c2G4 from ZMapp. The use of only two antibodies in MIL77E opens the door to a pan-ebolavirus cocktail. ..
  3. pmc Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
    ..These results indicate that MAbs particularly when used as an oligoclonal set are a potential therapeutic for post-exposure treatment of EBOV infection...
  4. doi request reprint Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
    ..All 8 MAb improved survival rates by 33%-100% against a high dose lethal challenge with mouse-adapted ZEBOV. This work has important implications for further development of vaccines and immunotherapies for ZEBOV infection...
  5. doi request reprint mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 5:207ra143. 2013
    ..This study describes conditions capable of saving 100% of EBOV-infected NHPs when initiated after the presence of detectable viremia along with symptoms. ..
  6. pmc Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Rep 3:3365. 2013
    ..The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure. ..
  7. doi request reprint Development and Characterization of a Guinea Pig-Adapted Sudan Virus
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 90:392-9. 2015
    ..These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV...
  8. doi request reprint Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology
    J Infect Dis 212:S379-83. 2015
    ..The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV. ..
  9. pmc Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
    Xiangguo Qiu
    National Laboratory for Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Nature 514:47-53. 2014
    ..ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use. ..
  10. doi request reprint Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, MB, R3E 3R2 Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Vaccine 32:5722-9. 2014
    ..These studies confirm that vaccination with VSVΔG/EBOVGP is able to confer long-term protection against Ebola infection in mice and guinea pigs, and support follow-up studies in non-human primates. ..
  11. doi request reprint Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study
    Jenna Aviles
    National Microbiology Laboratory, Public Health Agency of Canada University of Manitoba, Winnipeg, Canada
    J Infect Dis 212:S389-97. 2015
    ..Prime-boost regimens using independent vaccine platforms may provide a useful strategy to induce long-term immune protection against filoviruses. ..
  12. doi request reprint Immune Response to Marburg Virus Angola Infection in Nonhuman Primates
    Lisa Fernando
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 212:S234-41. 2015
    ..However, very little is known about the pathogenicity of MARV Angola, as few studies have been conducted to date. Therefore, the immune response was examined in MARV Angola-infected nonhuman primates...
  13. pmc Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 87:7754-7. 2013
    ..p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i...
  14. pmc Ebola virus transmission in guinea pigs
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    J Virol 89:1314-23. 2015
    ....
  15. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  16. doi request reprint Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Antiviral Res 116:17-9. 2015
    ..Prior vaccination resulted in robust levels of EBOV-specific antibodies and conferred complete protection in gps. These results support the use of vaccines to prevent EBOV transmission between hosts. ..
  17. doi request reprint Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:138ra81. 2012
    ..These data highlight the important role of antibodies to control EBOV replication in vivo, and support the use of mAbs against a severe filovirus infection...
  18. pmc Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure...
  19. doi request reprint Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, and Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    J Infect Dis 212:S435-42. 2015
    ....
  20. doi request reprint Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus
    Jonathan Audet
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada, R3E 0J9
    Sci Rep 4:6881. 2014
    ....
  21. pmc The multiple roles of sGP in Ebola pathogenesis
    Marc Antoine de La Vega
    1 Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Viral Immunol 28:3-9. 2015
    ..This review summarizes the multiple roles that sGP may play during infection and highlights the implications for the future design of vaccines and treatments...
  22. doi request reprint Post-exposure therapy of filovirus infections
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Trends Microbiol 22:456-63. 2014
    ....
  23. doi request reprint Characterization of host immune responses in Ebola virus infections
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street Winnipeg, MB, R3E 3R2 Canada
    Expert Rev Clin Immunol 10:781-90. 2014
    ..This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics...
  24. doi request reprint Development of experimental and early investigational drugs for the treatment of Ebola virus infections
    Gary Wong
    National Microbiology Laboratory, Public Health Agency of Canada, Special Pathogens Program, Winnipeg, Manitoba, Canada
    Expert Opin Investig Drugs 24:999-1011. 2015
    ..Concern among the public and authorities helped spark an unprecedented push to fast-track experimental drugs for clinical use...
  25. doi request reprint Progression of Ebola Therapeutics During the 2014-2015 Outbreak
    Emelissa J Mendoza
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Department of Immunology, University of Manitoba, Winnipeg, MB, Canada
    Trends Mol Med 22:164-73. 2016
    ....